The fund has 65 components. Top holdings include Cubist Pharmaceuticals 6.1%, Questcor Pharmaceuticals 5.9%, Centene 4.6%, Align Technology 4.6% and Parexel International 3.9%.
Market-capitalization includes mid-cap growth 10.6%, small-cap growth 72.9% and small-cap value 16.5%.
PSCH is up 33.9% year-to-date.
The SPDR S&P Biotech ETF (NYSEArca: XBI) tries to reflect the performance of the S&P Biotechnology Select Industry Index, which represents the biotech sector of the S&P Total Market Index. The underlying index also employs an equal-weight methodology. XBI has a 0.35% expense ratio.
The ETF holds 58 stocks. Top holdings include Alnyiam Pharmaceuticals 3.1%, NPS Pharmaceuticals 3.0%, Incyte Corp. 2.9%, InterMune 2.9% and Celldex Therapeutics 2.5%.
Market-capitalization includes giant-cap, 6.3%, large-cap 7.5%, mid-cap 26.1%, small-cap 36.5% and micro-cap 23.6%.
XBI is up 37.5% year-to-date.
For more information on the health care sector, visit our health care category.
Max Chen contributed to this article.